<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment regimens for Helicobacter pylori in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment regimens for Helicobacter pylori in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment regimens for Helicobacter pylori in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple antibiotic regimens have been evaluated for <em>Helicobacter pylori</em> (<em>H. pylori</em>)<em> </em>therapy [<a href="#rid1">1-6</a>]. However, few regimens have consistently achieved high eradication rates. There are also limited data on <em>H. pylori</em> antibiotic resistance rates to guide therapy. The treatment regimen that is selected must consider local antibiotic resistance patterns (if known), previous exposure and allergies to specific antibiotics, cost, side effects, and ease of administration.</p><p>This topic will review treatment regimens for <em>H. pylori</em>. The bacteriology, epidemiology, and diagnostic tests for <em>H. pylori</em> infection are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults"</a> and  <a class="medical medical_review" href="/d/html/16.html" rel="external">"Bacteriology and epidemiology of Helicobacter pylori infection"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120420">(Related Pathway(s):  <a class="utd-content-120420" href="/pathway/120420?topicRef=7&amp;source=see_link">Helicobacter pylori: Initial treatment for adults</a>.)</span></p><p class="headingAnchor" id="H4260690167"><span class="h1">INDICATIONS FOR TREATMENT</span><span class="headingEndMark"> — </span>All patients with evidence of active infection with <em>H. pylori </em>should be offered treatment. Indications for testing for <em>H. pylori</em> infection are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Indications for testing'</a>.)</p><p class="headingAnchor" id="H545843828"><span class="h1">INITIAL ANTIBIOTIC THERAPY</span></p><p class="headingAnchor" id="H3817818346"><span class="h2">Approach to selecting an antibiotic regimen</span><span class="headingEndMark"> — </span>The choice of initial antibiotic regimen to treat <em>H. pylori</em> should be guided by the presence of risk factors for macrolide resistance and the presence of a penicillin allergy [<a href="#rid7">7</a>]. In patients with one or more risk factors for macrolide resistance, clarithromycin-based therapy should be avoided. A suggested approach to the selection of antibiotics for initial treatment of <em>H. pylori</em> infection is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef112678" data-inline-graphics="112678" href="/d/graphic/112678.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef112171" data-inline-graphics="112171" href="/d/graphic/112171.html" rel="external">table 1</a>). (See <a class="local">'Clarithromycin-based therapy'</a> below.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120420">(Related Pathway(s):  <a class="utd-content-120420" href="/pathway/120420?topicRef=7&amp;source=see_link">Helicobacter pylori: Initial treatment for adults</a>.)</span></p><p>Risk factors for macrolide resistance include:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior exposure to macrolide therapy at any time for any reason</p><p class="bulletIndent1"><span class="glyph">●</span>High local <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> resistance rates ≥15 percent or eradication rates with clarithromycin triple therapy ≤85 percent</p><p></p><p>A resistance threshold of ≥15 percent is commonly used for choosing alternative empiric antibiotic regimen for <em>H. pylori</em> [<a href="#rid8">8,9</a>]. In the United States, given the limited information on antimicrobial resistance rates, we generally assume <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> resistance rates are greater than 15 percent unless local data indicate otherwise [<a href="#rid10">10</a>]. Data suggest that <em>H. pylori</em> antibiotic resistance rates are high worldwide. In a systematic review and meta-analysis that included 178 studies, comprising 66,142 isolates from 65 countries, primary and secondary resistance to clarithromycin, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, and <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> were high (≥15 percent) in the majority of WHO regions [<a href="#rid11">11</a>]. The pooled prevalence of primary clarithromycin resistance was &gt;15 percent in European, Eastern Mediterranean and Western regions but were lower in the Americas (10 percent, 95% CI 4-16) and the South East Asia region (10 percent, 95% CI 5-16). Resistance to clarithromycin was significantly associated with failure of <em>H. pylori</em> eradication with a clarithromycin-containing regimen (odds ratio, 6.97; 95% CI, 5.2-9.3). However, the study was limited by significant heterogeneity and 10 of the 13 studies contributing to the pooled data for the Americas region were derived from South America. Local surveillance data are needed guide the choice of eradication regimens.</p><p class="headingAnchor" id="H1285242199"><span class="h3">Patients with risk factors for macrolide resistance</span><span class="headingEndMark"> — </span>In patients with risk factors for macrolide resistance, we use bismuth quadruple therapy  (<a class="graphic graphic_algorithm graphicRef112678" href="/d/graphic/112678.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a>) [<a href="#rid7">7-9,12-16</a>]. (See <a class="local">'Bismuth quadruple therapy'</a> below and <a class="local">'Levofloxacin based therapy'</a> below.)</p><p class="headingAnchor" id="H2227870566"><span class="h3">Patients without risk factors for macrolide resistance</span><span class="headingEndMark"> — </span>In patients without risk factors for macrolide resistance, we use clarithromycin-based triple therapy with a proton pump inhibitor (PPI), <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, and <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>  (<a class="graphic graphic_algorithm graphicRef112678" href="/d/graphic/112678.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a>). Other first-line antibiotic regimens for these patients include bismuth quadruple therapy and clarithromycin-based concomitant therapy. In penicillin-allergic individuals, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> can be substituted for amoxicillin. In patients with metronidazole exposure within the past few years, we use bismuth quadruple therapy. (See <a class="local">'Clarithromycin-based therapy'</a> below and <a class="local">'Bismuth quadruple therapy'</a> below and <a class="local">'Concomitant therapy'</a> below.)</p><p>Other potential first-line treatment regimens include clarithromycin-based hybrid or sequential therapy [<a href="#rid7">7</a>]. However, the clarithromycin-based hybrid therapy has not been universally endorsed as an option for first-line therapy given its complexity [<a href="#rid8">8</a>]. In addition, some North American guidelines recommend against the use of sequential therapy as a first-line regimen given the lack of data from North American trials [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H740837509"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>We recommend clarithromycin-based triple therapy and bismuth quadruple treatment regimens for <em>H. pylori</em> be administered for 14 days. Our recommendations are largely consistent with guidelines that recommend extended (10 to 14 days) treatment with all antibiotic regimens for <em>H. pylori </em> (<a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a>) [<a href="#rid8">8,9,12</a>].</p><p class="headingAnchor" id="H1588496158"><span class="h2">Tolerability and compliance</span><span class="headingEndMark"> — </span>Side effects are reported in up to 50 percent of patients taking one of the triple therapy regimens [<a href="#rid3">3,17</a>]. The adverse effects are usually mild; fewer than 10 percent of patients stop treatment due to side effects [<a href="#rid17">17</a>]. Clarithromycin-based triple therapy and bismuth quadruple therapy appear to have similar efficacy, compliance, and tolerability [<a href="#rid18">18</a>]. While the tolerability and compliance of sequential, hybrid, and concomitant therapies appears to be similar to triple therapy in clinical trials, these regimens are more complex. Side effects of individual drugs are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/464.html" rel="external">"Metronidazole: An overview"</a> and  <a class="medical medical_review" href="/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'Adverse reactions'</a> and  <a class="medical medical_review" href="/d/html/494.html" rel="external">"Tetracyclines", section on 'Adverse reactions'</a> and  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/32.html" rel="external">"Antiulcer medications: Mechanism of action, pharmacology, and side effects", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H1032686964"><span class="h2">Antibiotic regimens</span><span class="headingEndMark"> — </span>Initial antibiotic regimens for <em>H. pylori </em>can be broadly divided into bismuth, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, and <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> containing regimens  (<a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef112678" href="/d/graphic/112678.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H4045763521"><span class="h3">Bismuth quadruple therapy</span><span class="headingEndMark"> — </span>Bismuth quadruple therapy consists of <a class="drug drug_general" data-topicid="101044" href="/d/drug information/101044.html" rel="external">bismuth subsalicylate</a>, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, and a PPI given for 14 days [<a href="#rid19">19</a>]. A combination capsule containing bismuth subcitrate, metronidazole, and tetracycline (Pylera) has been approved by the United States Food and Drug Administration. A regimen using the combination capsule (three capsules four times daily plus PPI twice daily) is somewhat simpler than standard quadruple therapy (four to eight pills four times daily and a PPI twice daily). For details, refer to <a class="drug drug_general" data-topicid="101645" href="/d/drug information/101645.html" rel="external">bismuth subcitrate-metronidazole-tetracycline</a> in Lexicomp. If tetracycline is not available, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily) may be substituted [<a href="#rid20">20,21</a>].</p><p>In North American trials, the mean eradication rate with bismuth quadruple therapy administered for 10 days was 91 percent [<a href="#rid12">12,22,23</a>]. A 2013 meta-analysis of 12 randomized trials reported comparable eradication rates with bismuth quadruple therapy and <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> triple therapy (78 and 69 percent, respectively) [<a href="#rid24">24</a>]. However, there was significant heterogeneity in treatment duration, drug dosing, and the meta-analysis included trials performed in North America, Europe, and Asia. No significant differences in efficacy were noted when both regimens were administered for 10 to 14 days. <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">Metronidazole</a> resistance has a limited impact on eradication success rate in patients treated with bismuth quadruple therapy and can be overcome by increasing the dose, duration, or frequency of therapy [<a href="#rid25">25</a>]. (See <a class="local">'Factors associated with antibiotic treatment failure'</a> below.)</p><p class="headingAnchor" id="H3453806024"><span class="h3">Clarithromycin-based therapy</span></p><p class="headingAnchor" id="H3153939224"><span class="h4">Triple therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">Clarithromycin</a> triple therapy consists of clarithromycin, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, and a PPI, all given twice daily  (<a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a>). We suggest treatment for 14 days, as longer duration of treatment may be more effective in curing infection [<a href="#rid7">7,8,26</a>]. <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">Metronidazole</a> can be used instead of amoxicillin in penicillin-allergic individuals. PPI-clarithromycin-metronidazole and PPI-clarithromycin-amoxicillin regimens are equivalent [<a href="#rid9">9,27</a>].</p><p>Eradication rates for <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> triple therapy in the United States are below 80 percent [<a href="#rid7">7</a>]. The eradication rates of clarithromycin triple therapy is significantly impacted by the presence of clarithromycin resistance [<a href="#rid18">18,24</a>]. In a meta-analysis of two trials in which patients were treated with clarithromycin triple therapy, eradication rates for clarithromycin-sensitive <em>H. pylori </em>strains and clarithromycin-resistant strains were 90 and 22 percent respectively [<a href="#rid18">18</a>]. Addition of bismuth to 14-day clarithromycin-based triple therapy may improve eradication rates in areas with high antimicrobial resistance [<a href="#rid28">28</a>]. However, further studies are needed.</p><p class="headingAnchor" id="H3788833783"><span class="h4">Concomitant therapy</span><span class="headingEndMark"> — </span>Concomitant therapy consists of a <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, a nitroimidazole (<a class="drug drug_general" data-topicid="10205" href="/d/drug information/10205.html" rel="external">tinidazole</a> or <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>), and a PPI administered together  (<a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a>). If concomitant therapy is used to treat <em>H. pylori,</em> the regimen should be continued for 10 to 14 days.</p><p>While efficacy data from the North America are lacking, in a meta-analysis of 19 randomized trials that included 2070 individuals in Europe, Asia and Latin America, eradication rates were significantly higher with concomitant quadruple therapy as compared with <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> triple therapy (90 and 78 percent, respectively) [<a href="#rid29">29</a>]. The efficacy of concomitant therapy was decreased in patients with clarithromycin-resistant <em>H. pylori </em>infection but to a smaller degree as compared with clarithromycin triple therapy. In this meta-analysis, longer durations of therapy (7 to 10 versus 3 to 5) were associated with a trend toward higher cure rates. However, additional studies are needed to assess whether extending the duration of concomitant therapy to 14 days results in improved eradication rates.</p><p class="headingAnchor" id="H1644077299"><span class="h4">Hybrid therapy</span><span class="headingEndMark"> — </span>Hybrid therapy consists of <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> and a PPI for seven days followed by amoxicillin, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, a nitroimidazole, and a PPI for seven days  (<a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a>). Hybrid therapy has been suggested as an alternative to clarithromycin triple therapy. However, the complexity of the treatment regimen has limited its use as a first-line regimen in the treatment of<em> H. pylori.</em></p><p>In a meta-analysis that included six randomized trials, which compared hybrid therapy with sequential and/or concomitant therapy, the eradication rate with hybrid therapy was 89 percent [<a href="#rid30">30</a>]. The efficacy and tolerability of hybrid therapy is comparable to concomitant and sequential regimens [<a href="#rid31">31</a>]. Hybrid therapy has not been directly compared with clarithromycin-based triple therapy. However, in one randomized trial in which 440 patients were assigned to 12 days of triple therapy or reverse hybrid therapy (<a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> and <a class="drug drug_general" data-topicid="9474" href="/d/drug information/9474.html" rel="external">pantoprazole</a> for 12 days and <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> plus <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> for the initial seven days), eradication rates were significantly higher with reverse hybrid therapy (96 versus 89 percent) [<a href="#rid32">32</a>]. In contrast to patients who received clarithromycin triple therapy, clarithromycin resistance did not significantly impact eradication rates in patients treated with reverse hybrid therapy.</p><p class="headingAnchor" id="H3158554386"><span class="h4">Sequential therapy</span><span class="headingEndMark"> — </span>The 10-day clarithromycin-containing sequential therapy regimen consists of <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> and a PPI for five days, followed by <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> and nitroimidazole (eg, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) plus a PPI for five days  (<a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a>) [<a href="#rid33">33</a>]. Given the complexity of the sequential therapy regimen and the lack of superiority to 14 day clarithromycin triple therapy in North America, clarithromycin-containing sequential therapy has not been uniformly endorsed by guidelines as a first-line therapy [<a href="#rid8">8</a>]. (See <a class="local">'Patients without risk factors for macrolide resistance'</a> above.)</p><p>In a 2013 meta-analysis of 46 randomized trials that included 13,532 patients who were assigned to sequential therapy or other regimens, the overall eradication rate for sequential therapy was 84 percent [<a href="#rid34">34</a>]. Eradication rates with sequential therapy were significantly higher as compared with <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> triple therapy administered for 7 or 10 days. However, there was no significant difference in eradication rates between sequential therapy and 14 days of clarithromycin-based triple therapy or 10 to 14 days of bismuth quadruple therapy. The efficacy of sequential therapy varies widely by region [<a href="#rid7">7</a>]. Randomized trials in Latin America and Asia have also demonstrated lower eradication rates with sequential therapy as compared with clarithromycin triple therapy; however, the efficacy of sequential therapy may be higher in Europe [<a href="#rid35">35-39</a>].</p><p class="headingAnchor" id="H2609998802"><span class="h3">Levofloxacin based therapy</span><span class="headingEndMark"> — </span>Due to rising rates of <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> resistance, levofloxacin should not be used for treatment unless the <em>H. pylori</em> strain is known to be sensitive to it or if the population levofloxacin resistance rates are known to be less than 15 percent [<a href="#rid7">7,11,40,41</a>]. Studies evaluating the efficacy of levofloxacin containing regimens in North America are lacking. Limited data suggest that fluoroquinolone resistance rates in North America are high [<a href="#rid11">11</a>]. Levofloxacin resistance decreases the eradication success rate of levofloxacin containing regimens by 20 to 40 percent [<a href="#rid7">7</a>]. (See <a class="local">'Approach to selecting an antibiotic regimen'</a> above and <a class="local">'Salvage regimens'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a><strong> triple therapy</strong> – Levofloxacin triple therapy consists of levofloxacin, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, and a PPI for 10 to 14 days. In a network meta-analysis eradication rates with levofloxacin triple therapy for 10 to 14 days were significantly higher than <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> triple therapy for seven days (90 versus 73 percent) [<a href="#rid31">31</a>]. Although not directly compared, the pooled eradication rate of levofloxacin triple therapy was also higher than clarithromycin triple therapy for 10 to 14 days (81 percent, 95% CI, 78 to 84 percent). <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">Metronidazole</a> can be substituted for amoxicillin in penicillin-allergic individuals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a><strong> quadruple therapy</strong> – Limited data support the use of quadruple therapy with levofloxacin, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a>, <a class="drug drug_general" data-topicid="10105" href="/d/drug information/10105.html" rel="external">nitazoxanide</a>, and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (LOAD). In an open label prospective trial, <em>H. pylori</em> treatment-naïve patients randomized to LOAD for 7 or 10 days had significantly higher eradication rates as compared with <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> triple therapy for 10 days (89, 90, and 73 percent, respectively) [<a href="#rid42">42</a>]. However, additional studies are needed to confirm these results and determine whether this more expensive regimen is cost-effective. Other levofloxacin-based quadruple therapy regimens that have been used as salvage therapy include PBLA (PPI, bismuth, levofloxacin, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>), PBLT (PPI, bismuth, levofloxacin, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>), and PBLM (PPI, bismuth, levofloxacin, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a> <strong>sequential</strong> <strong>therapy</strong> – Levofloxacin sequential therapy consists of <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> and a PPI for five to seven days followed by levofloxacin, amoxicillin, a nitroimidazole and a PPI for five to seven days. A meta-analysis of six international trials compared the efficacy of fluoroquinolone sequential therapy for 10 to 14 days and either <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> triple therapy for 7 to 14 days or standard sequential therapy for 10 days [<a href="#rid43">43</a>]. The pooled eradication rate with fluoroquinolone sequential therapy was significantly higher as compared with clarithromycin triple or standard sequential therapies combined (88 versus 71 percent).</p><p></p><p class="headingAnchor" id="H1142536193"><span class="h3">PCAB containing regimens</span><span class="headingEndMark"> — </span>Regimens containing vonoprazan, an oral potassium-competitive acid blocker (PCAB) as triple therapy with <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> and <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> (<a class="drug drug_general" data-topicid="138608" href="/d/drug information/138608.html" rel="external">vonoprazan-amoxicillin-clarithromycin</a>) or as dual therapy with high-dose amoxicillin (<a class="drug drug_general" data-topicid="138609" href="/d/drug information/138609.html" rel="external">vonoprazan-amoxicillin</a>), are associated with high <em>H. pylori</em> eradication rates [<a href="#rid44">44-47</a>]. Vonoprazan triple therapy may be an option for initial treatment in areas of low clarithromycin resistance rates. However, in areas with high or unknown clarithromycin resistance, further studies are needed to compare eradication rates with bismuth quadruple therapy [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/32.html" rel="external">"Antiulcer medications: Mechanism of action, pharmacology, and side effects", section on 'Potassium-competitive acid inhibitors'</a>.)</p><p class="headingAnchor" id="H1650484992"><span class="h1">CONFIRM ERADICATION IN ALL PATIENTS</span><span class="headingEndMark"> — </span>Tests to confirm eradication should be performed in all patients treated for <em>H. pylori</em>. Eradication may be confirmed by a urea breath test, fecal antigen test, or upper endoscopy performed four weeks or more after completion of antibiotic therapy. PPI therapy should be withheld for one to two weeks prior to testing [<a href="#rid12">12,40,48</a>]. Endoscopy with biopsy for culture and sensitivity should be performed in patients with persistent <em>H. pylori</em> infection after two courses of antibiotic treatment [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Confirm eradication in all patients'</a>.)</p><p class="headingAnchor" id="H3635965466"><span class="h1">TREATMENT FAILURE</span><span class="headingEndMark"> — </span>Approximately 20 percent of patients fail an initial attempt at <em>H. pylori</em> eradication [<a href="#rid49">49</a>]. Such patients require salvage therapy  (<a class="graphic graphic_algorithm graphicRef112679" href="/d/graphic/112679.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef112172" href="/d/graphic/112172.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3167044966"><span class="h2">Factors associated with antibiotic treatment failure</span><span class="headingEndMark"> — </span>Factors associated with treatment failure include poor patient compliance and resistance of the patient’s <em>H. pylori </em>strain to prescribed antibiotics. <em>H. pylori</em> is naturally resistant to several commonly used antibiotics, including <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a>, and sulfonamides [<a href="#rid50">50</a>]. A specific mutation leading to <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> resistance appears to be associated with a reduced likelihood of eradication [<a href="#rid51">51</a>]. Prior use of macrolide antibiotics, and <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> increases the risk of <em>H. pylori</em> resistance to these antibiotics [<a href="#rid52">52</a>]. Clarithromycin resistance has a greater effect on treatment efficacy as compared with <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> resistance [<a href="#rid25">25</a>]. Resistance rates to <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, and <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> are low (&lt;5 percent), and these can be considered for subsequent therapies in refractory <em>H. pylori</em> infection [<a href="#rid41">41</a>]. Inadequate acid suppression is also associated with <em>H. pylori</em> eradication failure.</p><p class="headingAnchor" id="H6"><span class="h2">Salvage therapy for persistent H. pylori infection</span></p><p class="headingAnchor" id="H2267030540"><span class="h3">Suggested approach</span><span class="headingEndMark"> — </span>In patients with persistent <em>H. pylori </em>infection, the choice of antibiotic therapy should be guided by the patient’s initial treatment regimen, the use of other antibiotics, and the presence of relevant antibiotic allergies [<a href="#rid41">41</a>]. Antibiotics included in the initial regimen should generally be avoided [<a href="#rid53">53</a>]. However, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> can be reused as resistance rarely develops. Patients with a reported history of penicillin allergy should be referred to an allergist to determine if they have a true penicillin allergy. A suggested approach to the selection of antibiotics for persistent <em>H. pylori</em> infection is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef112679" data-inline-graphics="112679" href="/d/graphic/112679.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef112172" href="/d/graphic/112172.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/2079.html" rel="external">"An approach to the patient with drug allergy"</a>.)</p><p>Culture with antibiotic sensitivity testing should be performed to guide antibiotic treatment in patients who have failed two prior treatment regimens. Compliance with medications should also be reinforced. We reserve the use of rifabutin-containing regimens for patients with ≥3 previous antibiotic failures. However, other experts have suggested its use as a second-line agent [<a href="#rid41">41</a>]. The impact of <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> resistance can be overcome by increasing the dose (1.5 to 2 g daily in divided doses), duration, or frequency of administration of metronidazole [<a href="#rid41">41</a>]. Resistance rates to <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, and <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> are low (&lt;5 percent), and these can be considered for subsequent therapies in refractory <em>H. pylori</em> infection even if previously used [<a href="#rid41">41</a>].</p><p>The use of high-dose PPIs (double the standard dose), use of more potent PPIs and those less dependent on metabolism by CYP2C19 (eg, <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a> or <a class="drug drug_general" data-topicid="9519" href="/d/drug information/9519.html" rel="external">rabeprazole</a>), or potassium-competitive acid blockers where available, can lower intragastric acidity in patients with refractory <em>H. pylori</em> infection [<a href="#rid41">41,54</a>]. (See  <a class="medical medical_review" href="/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Bacterial culture and sensitivity testing'</a>.)</p><p class="headingAnchor" id="H1181944356"><span class="h3">Salvage regimens</span><span class="headingEndMark"> — </span>Salvage regimens in patients who have failed initial antibiotic therapy include  (<a class="graphic graphic_table graphicRef112172" data-inline-graphics="112172" href="/d/graphic/112172.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bismuth quadruple therapy</strong> – Bismuth quadruple therapy should be used for 14 days when used as salvage regimen. In randomized trials performed in Europe, United States, and Asia eradication rates with 14-day salvage bismuth quadruple therapy were approximately 80 percent [<a href="#rid12">12</a>]. Eradication rates were significantly higher in studies performed in Asia as compared with Europe and the United States (82 versus 74 percent) [<a href="#rid55">55-57</a>]. The overall eradication rate for 14-day bismuth quadruple therapy in these trials was higher in patients who had previously failed clarithromycin-based regimens without bismuth as compared with bismuth quadruple treatment (100 versus 53 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Levofloxacin-based therapy</strong> – Levofloxacin-based triple therapy has demonstrated efficacy as a salvage regimen in patients who have failed initial <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> triple therapy or bismuth quadruple therapy. <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a> triple therapy has also demonstrated efficacy in patients who have failed two prior attempts at treatment. In a pooled analysis from six European cohort studies, when used as a salvage regimen in patients who had failed two previous eradication attempts, levofloxacin triple therapy administered for 10 days has a pooled eradication rate of 73 percent [<a href="#rid58">58</a>]. Most patients in these studies were treated with clarithromycin triple therapy followed by bismuth quadruple therapy.</p><p></p><p class="bulletIndent1">Other levofloxacin-based quadruple therapy regimens that have been used as salvage therapy include PBLA (PPI, bismuth, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>), PBLT (PPI, bismuth, levofloxacin, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>), and PBLM (PPI, bismuth, levofloxacin, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-dose dual therapy</strong> – High-dose dual therapy with <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> (at least 2 g divided three or four times per day to avoid low trough levels) and proton pump inhibitor (PPI) for 14 days is a salvage treatment option, particularly in patients in whom dual <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>/<a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> resistance or <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> resistance is suspected [<a href="#rid41">41</a>]. The pooled eradication rate of high-dose dual therapy with amoxicillin and PPI as a salvage regimen in three randomized trials performed in Europe and Asia was 78 percent [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">The role of high-dose dual therapy as first-line treatment is unclear, as studies evaluating the efficacy of this regimen have been conflicting. In studies conducted in the United States and Korea, eradication rates in treatment-naive patients were low (72 and 79 percent, respectively) [<a href="#rid59">59,60</a>]. However, in a randomized trial in China in which 232 treatment-naive patients were assigned to high-dose dual therapy or bismuth quadruple therapy, there was no significant difference in eradication rates between the two groups [<a href="#rid61">61</a>]. While high-dose dual therapy had lower treatment-related adverse effects as compared with bismuth quadruple therapy, it is important to note that there may have been reporting bias due to the open-label study design.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">Rifabutin</a><strong> triple therapy</strong> – Rifabutin triple therapy has demonstrated efficacy as a salvage regimen. The rifabutin-based triple regimen consists of rifabutin, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, and a PPI twice daily for 14 days. In randomized trial, in which 364 subjects with <em>H. pylori</em> who had failed at least two prior treatments were randomly assigned to rifabutin triple therapy for 14 days or bismuth quadruple therapy, there was no significant difference in <em>H. pylori</em> eradication rates [<a href="#rid62">62</a>]. However, compliance rates were higher in patients treated with rifabutin-based triple therapy as compared with the bismuth quadruple therapy (96 versus 85 percent), and the rates of adverse effects were significantly lower (26 versus 54 percent). The most frequent adverse effects of rifabutin triple therapy were fever and skin rash (12 and 8 percent, respectively). Five subjects with fever experienced transient leukopenia. Limitations of this study include the potential risk of bias and lack of blinding.  </p><p></p><p class="bulletIndent1">The role of rifabutin-based triple therapy as a first-line treatment option is unclear. In a randomized trial, in which 4<em>55 H. pylori</em> treatment-naïve patients were assigned to treatment with rifabutin-based triple therapy or high-dose dual therapy with <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> and <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a>, eradication rates with the rifabutin-containing regimen were significantly higher (84 versus 58 percent) [<a href="#rid63">63</a>]. Eradication rates were unaffected by resistance to <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> or <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>. However, the study was conducted in the United States and excluded persons of Asian descent due to a higher prevalence of poor CYP2C19 metabolizers. Rifabutin-based triple therapy is expensive and can cause reversible myelotoxicity. It also has the potential to increase the prevalence of rifabutin-resistant mycobacteria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clarithromycin-based therapy</strong> – Clarithromycin-based therapy (eg, PPI, bismuth, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>), can be used as a salvage regimen in patients with no risk factors for macrolide resistance (no prior macrolide exposure and local clarithromycin resistance known to be &lt;15 percent) [<a href="#rid41">41,64,65</a>]. (See <a class="local">'Clarithromycin-based therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H17104517"><span class="h1">ADJUVANT THERAPIES WITH UNCLEAR ROLE</span><span class="headingEndMark"> — </span>A number of potential adjuvant therapies for <em>H. pylori</em> have been evaluated, but additional studies are needed to support their use.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins</strong> – Addition of statin therapy as an adjuvant to triple therapy has been associated with a reduction in <em>H. pylori</em> mediated inflammation and an increase in <em>H. pylori</em> eradication rates [<a href="#rid66">66-68</a>]. However, large trials are needed to confirm these findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probiotics </strong>– Probiotics may have an inhibitory effect on <em>H. pylori. </em>In addition, they may improve compliance with treatment by<em> </em>reducing antibiotic side effects. A meta-analysis that included 10 clinical trials of adjuvant probiotics in patients with <em>H. pylori </em>infection demonstrated higher cure rates and a reduction in the incidence of side effects in patients who received probiotic supplementation (pooled OR 2.1 and 0.3, respectively). However, studies included in this meta-analysis were at high risk of bias due to lack of blinding and inadequate allocation concealment. In addition, there was significant variability in the probiotics used and antibiotic treatment regimens to eradicate <em>H. pylori</em>. (See  <a class="medical medical_review" href="/d/html/2603.html" rel="external">"Probiotics for gastrointestinal diseases"</a>.)</p><p></p><p class="headingAnchor" id="H3584616337"><span class="h1">TREATMENT DURING PREGNANCY AND LACTATION</span><span class="headingEndMark"> — </span>When peptic ulcer disease is diagnosed in a woman who is pregnant, the mainstay of treatment is typically acid suppression [<a href="#rid69">69</a>]. If <em>H. pylori</em> is present, treatment is typically deferred until after delivery. However, with the exception of bismuth, fluoroquinolones, and <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, the other medications used for <em>H. pylori</em> eradication are low risk in pregnancy, especially after 14 weeks. This includes <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, and probably <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>. Moreover, there is some evidence that <em>H. pylori</em> can cause severe nausea and vomiting in pregnancy, including hyperemesis gravidarum [<a href="#rid70">70,71</a>]. Thus, if indicated, <em>H. pylori</em> treatment should be considered in pregnancy.</p><p>Some of the medications typically used for the treatment of <em>H. pylori</em> are possibly unsafe for nursing infants (eg, bismuth, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>). (See  <a class="medical medical_review" href="/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults", section on 'Pregnancy and lactation'</a> and  <a class="medical medical_review" href="/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Antibiotics'</a>.)</p><p class="headingAnchor" id="H2746670566"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110246.html" rel="external">"Society guideline links: <i>Helicobacter pylori</i>"</a>.)</p><p class="headingAnchor" id="H8690641"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15734.html" rel="external">"Patient education: H. pylori infection (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16944.html" rel="external">"Patient education: Gastritis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/2012.html" rel="external">"Patient education: Helicobacter pylori infection and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of initial antibiotic</strong> – All patients with evidence of active infection with <em>Helicobacter pylori </em>(<em>H. pylori</em>)<em> </em>should be offered treatment. The choice of initial antibiotic regimen to treat <em>H. pylori</em> should be guided by the presence of risk factors for macrolide resistance and the presence of a penicillin allergy.</p><p></p><p class="bulletIndent1">Risk factors for macrolide resistance include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior exposure to macrolide therapy at any time for any reason.</p><p class="bulletIndent2"><span class="glyph">•</span>High local <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> resistance rates ≥15 percent or eradication rates with clarithromycin-based triple therapy ≤85 percent.</p><p></p><p class="bulletIndent1">In the United States, given the limited information on antimicrobial resistance rates, we generally assume <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> resistance rates are greater than 15 percent unless local resistance data indicate otherwise. (See <a class="local">'Approach to selecting an antibiotic regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with risk factors for macrolide resistance</strong> – We suggest bismuth quadruple therapy as initial treatment in patients with risk factors for macrolide resistance (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>)  (<a class="graphic graphic_algorithm graphicRef112678" href="/d/graphic/112678.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a>). Quadruple therapy consists of a proton pump inhibitor (PPI), <a class="drug drug_general" data-topicid="101044" href="/d/drug information/101044.html" rel="external">bismuth subsalicylate</a>, and two antibiotics (<a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> and <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>) given four times daily for 14 days. Alternatively, a commercially available combination capsule containing bismuth subsalicylate, metronidazole, and tetracycline may be used in conjunction with a PPI. In patients with risk factors for macrolide resistance, clarithromycin-based therapy should be avoided  (<a class="graphic graphic_algorithm graphicRef112678" href="/d/graphic/112678.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef112171" href="/d/graphic/112171.html" rel="external">table 1</a>). (See <a class="local">'Patients with risk factors for macrolide resistance'</a> above and <a class="local">'Bismuth quadruple therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without risk factors for macrolide resistance</strong> – For initial therapy in patients without risk factors for macrolide resistance, we suggest triple therapy with a PPI, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> (1 g twice daily), and <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> (500 mg twice daily) for 14 days (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Only in penicillin-allergic individuals, we suggest substitution of amoxicillin with <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> since metronidazole resistance is common and can reduce the efficacy of treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Clarithromycin-based therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirmation of eradication</strong> – Tests to confirm eradication should be performed in all patients treated for <em>H. pylori</em>. Eradication may be confirmed by a urea breath test, fecal antigen test, or upper endoscopy performed four weeks or more after completion of antibiotic therapy. PPI therapy should be withheld for one to two weeks prior to testing. (See <a class="local">'Confirm eradication in all patients'</a> above and  <a class="medical medical_review" href="/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Diagnostic tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of antibiotic treatment failure </strong>– In patients with persistent <em>H. pylori </em>infection, the choice of antibiotic therapy should be guided by the patient's initial treatment regimen and the presence of relevant antibiotic allergies  (<a class="graphic graphic_algorithm graphicRef112679" href="/d/graphic/112679.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef112172" href="/d/graphic/112172.html" rel="external">table 2</a>). For patients failing a course of <em>H. pylori</em> treatment, we suggest an alternate regimen using a different combination of medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). In general, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> and antibiotics used previously should be avoided if possible. (See <a class="local">'Salvage therapy for persistent H. pylori infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation in patients with two antibiotic failures</strong> – Culture with antibiotic sensitivity testing should be performed to guide antibiotic treatment in patients who have failed two prior treatment regimens. Compliance with medications should also be reinforced. We reserve the use of rifabutin-containing regimens for patients with ≥3 prior antibiotic failures. (See <a class="local">'Salvage therapy for persistent H. pylori infection'</a> above.)</p><p></p><p class="headingAnchor" id="H3705579128"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Crowe SE. Helicobacter pylori Infection. N Engl J Med 2019; 380:1158.</a></li><li><a class="nounderline abstract_t">Qasim A, Sebastian S, Thornton O, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21:91.</a></li><li><a class="nounderline abstract_t">Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20:1071.</a></li><li><a class="nounderline abstract_t">Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22:45.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 2005; 10:157.</a></li><li><a class="nounderline abstract_t">Graham DY, Hammoud F, El-Zimaity HM, et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 17:1229.</a></li><li><a class="nounderline abstract_t">Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112:212.</a></li><li><a class="nounderline abstract_t">Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016; 151:51.</a></li><li><a class="nounderline abstract_t">Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646.</a></li><li><a class="nounderline abstract_t">Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10:1088.</a></li><li><a class="nounderline abstract_t">Savoldi A, Carrara E, Graham DY, et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155:1372.</a></li><li><a class="nounderline abstract_t">Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808.</a></li><li><a class="nounderline abstract_t">Graham DY, Shiotani A. Which Therapy for Helicobacter pylori Infection? Gastroenterology 2012; 143:10.</a></li><li><a class="nounderline abstract_t">Tepes B, O'Connor A, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2012. Helicobacter 2012; 17 Suppl 1:36.</a></li><li><a class="nounderline abstract_t">Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: sequential therapy for Helicobacter pylori eradication in children. Aliment Pharmacol Ther 2012; 36:534.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34:1255.</a></li><li><a class="nounderline abstract_t">de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995; 30:401.</a></li><li><a class="nounderline abstract_t">Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105:65.</a></li><li><a class="nounderline abstract_t">McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362:1597.</a></li><li><a class="nounderline abstract_t">Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J 2012; 53:273.</a></li><li><a class="nounderline abstract_t">Akyildiz M, Akay S, Musoglu A, et al. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Eur J Intern Med 2009; 20:53.</a></li><li><a class="nounderline abstract_t">Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98:562.</a></li><li><a class="nounderline abstract_t">Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377:905.</a></li><li><a class="nounderline abstract_t">Venerito M, Krieger T, Ecker T, et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88:33.</a></li><li><a class="nounderline abstract_t">Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26:343.</a></li><li><a class="nounderline abstract_t">Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; :CD008337.</a></li><li><a class="nounderline abstract_t">Gisbert JP, González L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14:1319.</a></li><li><a class="nounderline abstract_t">McNicholl AG, Bordin DS, Lucendo A, et al. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol 2020; 18:89.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5:23.</a></li><li><a class="nounderline abstract_t">Wang B, Wang YH, Lv ZF, et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20:79.</a></li><li><a class="nounderline abstract_t">Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015; 351:h4052.</a></li><li><a class="nounderline abstract_t">Hsu PI, Kao SS, Wu DC, et al. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. Medicine (Baltimore) 2015; 94:e2104.</a></li><li><a class="nounderline abstract_t">Moayyedi P, Malfertheiner P. Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol 2009; 104:3081.</a></li><li><a class="nounderline abstract_t">Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347:f4587.</a></li><li><a class="nounderline abstract_t">Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104:3069.</a></li><li><a class="nounderline abstract_t">Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507.</a></li><li><a class="nounderline abstract_t">Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381:205.</a></li><li><a class="nounderline abstract_t">Albrecht P, Kotowska M, Szajewska H. Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial. J Pediatr 2011; 159:45.</a></li><li><a class="nounderline abstract_t">Bontems P, Kalach N, Oderda G, et al. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011; 53:646.</a></li><li><a class="nounderline abstract_t">Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017; 64:991.</a></li><li><a class="nounderline abstract_t">Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021; 160:1831.</a></li><li><a class="nounderline abstract_t">Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106:1970.</a></li><li><a class="nounderline abstract_t">Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis. Pharmacotherapy 2015; 35:719.</a></li><li><a class="nounderline abstract_t">Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65:1439.</a></li><li><a class="nounderline abstract_t">Sakurai K, Suda H, Ido Y, et al. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017; 23:668.</a></li><li><a class="nounderline abstract_t">Chey WD, Mégraud F, Laine L, et al. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022; 163:608.</a></li><li><a class="nounderline abstract_t">Fallone CA. The Current Role of Vonoprazan in Helicobacter pylori Treatment. Gastroenterology 2022; 163:572.</a></li><li><a class="nounderline abstract_t">Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66:6.</a></li><li><a class="nounderline abstract_t">Vakil N. Primary and secondary treatment for Helicobacter pylori in the United States. Rev Gastroenterol Disord 2005; 5:67.</a></li><li><a class="nounderline abstract_t">van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1:6.</a></li><li><a class="nounderline abstract_t">De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144:94.</a></li><li><a class="nounderline abstract_t">McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139:463.</a></li><li><a class="nounderline abstract_t">Malfertheiner P, Leodolter A, Peitz U. Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:119.</a></li><li><a class="nounderline abstract_t">Miner P, Delemos B, Xiang J, et al. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. Aliment Pharmacol Ther 2010; 31:991.</a></li><li><a class="nounderline abstract_t">Magaret N, Burm M, Faigel D, et al. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis 2001; 19:174.</a></li><li><a class="nounderline abstract_t">Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8:310.</a></li><li><a class="nounderline abstract_t">Cao Z, Chen Q, Zhang W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol 2015; 50:1185.</a></li><li><a class="nounderline abstract_t">Gisbert JP, H. pylori Study Group of the Spanish Gastroenterology Association. Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35:1484.</a></li><li><a class="nounderline abstract_t">Graham DY, Javed SU, Keihanian S, et al. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol 2010; 45:816.</a></li><li><a class="nounderline abstract_t">Kwack W, Lim Y, Lim C, Graham DY. High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea. Gastroenterol Res Pract 2016; 2016:1648047.</a></li><li><a class="nounderline abstract_t">Yang J, Zhang Y, Fan L, et al. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori. Am J Gastroenterol 2019; 114:437.</a></li><li><a class="nounderline abstract_t">Chen J, Guo Y, Huang Y, et al. Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial. J Infect Dis 2023; 228:511.</a></li><li><a class="nounderline abstract_t">Graham DY, Canaan Y, Maher J, et al. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med 2020; 172:795.</a></li><li><a class="nounderline abstract_t">Lamouliatte H, Mégraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003; 18:791.</a></li><li><a class="nounderline abstract_t">Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62:34.</a></li><li><a class="nounderline abstract_t">Nseir W, Diab H, Mahamid M, et al. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. Aliment Pharmacol Ther 2012; 36:231.</a></li><li><a class="nounderline abstract_t">Yamato M, Watanabe T, Higuchi K, et al. Anti-inflammatory effects of pravastatin on Helicobacter pylori-induced gastritis in mice. Dig Dis Sci 2007; 52:2833.</a></li><li><a class="nounderline abstract_t">Liao WC, Huang MZ, Wang ML, et al. Statin Decreases Helicobacter pylori Burden in Macrophages by Promoting Autophagy. Front Cell Infect Microbiol 2016; 6:203.</a></li><li><a class="nounderline abstract_t">Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131:283.</a></li><li><a class="nounderline abstract_t">Golberg D, Szilagyi A, Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet Gynecol 2007; 110:695.</a></li><li><a class="nounderline abstract_t">Mansour GM, Nashaat EH. Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum. Arch Gynecol Obstet 2011; 284:843.</a></li></ol></div><div id="topicVersionRevision">Topic 7 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30893536" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Helicobacter pylori Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644050" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569109" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963079" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15904473" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12755836" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28071659" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27102658" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491499" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15207062" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29990487" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17608775" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : American College of Gastroenterology guideline on the management of Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22613622" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Which Therapy for Helicobacter pylori Infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22958154" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of Helicobacter pylori infection 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22827718" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Meta-analysis: sequential therapy for Helicobacter pylori eradication in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22017749" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7638563" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19755966" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427808" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical practice. Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511052" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237093" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12650788" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21345487" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23880479" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635369" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24338763" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Optimum duration of regimens for Helicobacter pylori eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11012477" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30978536" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22457599" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25381839" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26290044" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26632893" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19956122" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23926315" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19844205" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777974" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23158886" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371717" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21701406" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541262" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33524402" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989146" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26173786" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26935876" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28216974" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35679950" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35780869" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The Current Role of Vonoprazan in Helicobacter pylori Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27707777" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15976737" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary and secondary treatment for Helicobacter pylori in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398908" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of Helicobacter pylori infection: a review of the world literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418408" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13679322" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10749093" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cure of Helicobacter pylori-associated ulcer disease through eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132153" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549829" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12950604" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25881966" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22582841" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20195646" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27413365" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30807294" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37079894" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32365359" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14535872" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22580412" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22646167" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404852" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Anti-inflammatory effects of pravastatin on Helicobacter pylori-induced gastritis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28144585" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Statin Decreases Helicobacter pylori Burden in Macrophages by Promoting Autophagy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16831611" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17766620" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079980" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
